IP6K1

Summary

IP6K1 (inositol hexakisphosphate kinase 1, HGNC:18360) is a protein-coding gene on chromosome 3p21.31, encoding Inositol hexakisphosphate kinase 1 (Q92551). Converts inositol hexakisphosphate (InsP6) to diphosphoinositol pentakisphosphate (InsP7/PP-InsP5).

This gene encodes a member of the inositol phosphokinase family. The encoded protein may be responsible for the conversion of inositol hexakisphosphate (InsP6) to diphosphoinositol pentakisphosphate (InsP7/PP-InsP5). It may also convert 1,3,4,5,6-pentakisphosphate (InsP5) to PP-InsP4. Alternatively spliced transcript variants have been described.

Source: NCBI Gene 9807 — RefSeq curated summary.

At a glance

• GWAS associations: 27
• Clinical variants (ClinVar): 47 total
• Druggable target: yes
• MANE Select transcript: NM_153273

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:18360
Approved symbol	IP6K1
Name	inositol hexakisphosphate kinase 1
Location	3p21.31
Locus type	gene with protein product
Status	Approved
Aliases	KIAA0263
Ensembl gene	ENSG00000176095
Ensembl biotype	protein_coding
OMIM	606991
Entrez	9807

Gene structure

Transcript identifiers

Ensembl transcripts: 17 — 13 protein_coding, 3 protein_coding_CDS_not_defined, 1 retained_intron

ENST00000321599, ENST00000395238, ENST00000460540, ENST00000468463, ENST00000479464, ENST00000495152, ENST00000495798, ENST00000498149, ENST00000613416, ENST00000853567, ENST00000853568, ENST00000853569, ENST00000853570, ENST00000853571, ENST00000853572, ENST00000853573, ENST00000948636

RefSeq mRNA: 3 — MANE Select: NM_153273 NM_001006115, NM_001242829, NM_153273

CCDS: CCDS33760, CCDS43092

Canonical transcript exons

ENST00000321599 — 6 exons

Exon	Start	End
ENSE00001242677	49728103	49728278
ENSE00001856162	49724294	49727655
ENSE00001868562	49786354	49786542
ENSE00003485470	49732791	49732972
ENSE00003509511	49747818	49748168
ENSE00003567137	49738212	49738422

Expression profiles

Bgee: expression breadth ubiquitous, 252 present calls, max score 93.83.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 36.4724 / max 371.3092, expressed in 1816 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
42276	36.4212	1816
42275	0.0512	14

Top tissues by expression

284 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
paraflocculus	UBERON:0005351	93.83	gold quality
middle frontal gyrus	UBERON:0002702	93.42	gold quality
right frontal lobe	UBERON:0002810	93.23	gold quality
frontal pole	UBERON:0002795	93.05	gold quality
cortical plate	UBERON:0005343	92.84	gold quality
prefrontal cortex	UBERON:0000451	92.74	gold quality
right hemisphere of cerebellum	UBERON:0014890	92.73	gold quality
cerebellar hemisphere	UBERON:0002245	92.60	gold quality
Brodmann (1909) area 10	UBERON:0013541	92.59	gold quality
cerebellar cortex	UBERON:0002129	92.58	gold quality
stromal cell of endometrium	CL:0002255	92.45	gold quality
cerebellum	UBERON:0002037	92.26	gold quality
frontal cortex	UBERON:0001870	92.04	gold quality
neocortex	UBERON:0001950	91.75	gold quality
cingulate cortex	UBERON:0003027	91.46	gold quality
anterior cingulate cortex	UBERON:0009835	91.42	gold quality
Brodmann (1909) area 9	UBERON:0013540	91.37	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	91.00	gold quality
cerebellar vermis	UBERON:0004720	90.82	gold quality
cerebral cortex	UBERON:0000956	90.61	gold quality
nucleus accumbens	UBERON:0001882	90.51	gold quality
ventricular zone	UBERON:0003053	90.31	gold quality
ganglionic eminence	UBERON:0004023	90.18	gold quality
telencephalon	UBERON:0001893	90.12	gold quality
islet of Langerhans	UBERON:0000006	90.07	gold quality
left testis	UBERON:0004533	89.77	gold quality
brain	UBERON:0000955	89.70	gold quality
forebrain	UBERON:0001890	89.69	gold quality
amygdala	UBERON:0001876	89.63	gold quality
central nervous system	UBERON:0001017	89.61	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

85 targeting IP6K1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-190A-3P	100.00	80.35	5520
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-4476	100.00	68.18	2030
HSA-MIR-6876-5P	100.00	67.68	2126
HSA-MIR-3667-3P	99.99	67.17	1636
HSA-MIR-512-3P	99.97	67.35	1049
HSA-MIR-539-5P	99.93	70.30	2855
HSA-MIR-497-5P	99.92	71.83	2674
HSA-MIR-589-3P	99.91	69.62	2088
HSA-MIR-652-5P	99.91	67.49	505
HSA-MIR-15A-5P	99.90	72.80	2787
HSA-MIR-15B-5P	99.90	72.78	2798
HSA-MIR-16-5P	99.90	72.80	2780
HSA-MIR-195-5P	99.90	72.81	2805
HSA-MIR-548E-5P	99.89	72.73	4486
HSA-MIR-424-5P	99.89	71.90	2641
HSA-MIR-6838-5P	99.89	71.94	2690
HSA-LET-7A-2-3P	99.87	70.53	1921
HSA-MIR-4492	99.87	68.25	3611
HSA-LET-7G-3P	99.85	70.43	1929
HSA-MIR-4728-5P	99.85	69.39	4718
HSA-MIR-6785-5P	99.82	68.68	4428
HSA-MIR-8076	99.78	68.52	1170
HSA-MIR-6764-5P	99.75	67.89	2304
HSA-MIR-4306	99.72	70.50	3630
HSA-MIR-6752-3P	99.72	66.71	1587
HSA-MIR-149-3P	99.72	68.22	3963
HSA-MIR-6883-5P	99.69	68.05	3785
HSA-MIR-3202	99.66	67.70	2737
HSA-MIR-9851-3P	99.63	69.68	1110

Literature-anchored findings (GeneRIF, showing 13)

• IHPK1 gene is disrupted at the 3p21.31 breakpoint of t(3;9) in a family with type 2 diabetes mellitus (PMID:15221640)
• Results report the characterization of an inhibitor, N(2)-(m-(trifluoromethy)lbenzyl) N(6)-(p-nitrobenzyl)purine (TNP), selective for inositol hexakisphosphate kinases. (PMID:19208622)
• FGF2-signaling involves the inositol polyphosphate cascade, including inositol hexakisphosphate kinase (IP6K), and demonstrate that IP6K1,2 regulates Runx2 and osteoblast gene expression. (PMID:23322705)
• we identified IP6Ks as novel nuclear and cytosolic InsP6- (and InsP5-) dephosphorylating enzymes whose activity is sensitively driven by a decrease in the cellular ATP/ADP ratio (PMID:24865181)
• IP6K1 is a novel CRL4 subunit that transduces UV signals to mediate disassembly of the CRL4-CSN complex, thereby regulating nucleotide excision repair and cell death. (PMID:25349427)
• IP6K1 is also involved in early cytoskeleton remodeling events during cancer progression. (PMID:27140681)
• provides the first evidence for the involvement of IP6Ks in dynein function and proposes that inositol pyrophosphate-mediated pyrophosphorylation may act as a regulatory signal to enhance dynein-driven transport (PMID:27474409)
• IP6K1 physiologically regulates neuronal migration by binding to alpha-actinin and influencing phosphorylation of both FAK and alpha-actinin through its product 5-diphosphoinositol pentakisphosphate. (PMID:28154132)
• the unique metabolic sensing properties of IP6K1 guarantees appropriate concentrations of IP7 and thereby both correct basal insulin secretion and intact first phase insulin release. (PMID:29522819)
• conclude that IP6K1 and -2 together control inositol pyrophosphate metabolism and thereby physiologically regulate phosphate export and other aspects of mammalian cellular phosphate homeostasis (PMID:31186349)
• miR-125a-5p impairs the metastatic potential in breast cancer via IP6K1 targeting. (PMID:34229060)
• Pleiotropic actions of IP6K1 mediate hepatic metabolic dysfunction to promote nonalcoholic fatty liver disease and steatohepatitis. (PMID:34757046)
• IP6K1 upregulates the formation of processing bodies by influencing protein-protein interactions on the mRNA cap. (PMID:34841428)

Cross-species orthologs

7 orthologs

Organism	Symbol	Gene ID
danio_rerio	ip6k1	ENSDARG00000073744
mus_musculus	Ip6k1	ENSMUSG00000032594
rattus_norvegicus	Ip6k1	ENSRNOG00000085966
drosophila_melanogaster	IP3K1	FBGN0032147
drosophila_melanogaster	Ip6k	FBGN0034644
caenorhabditis_elegans	lfe-2	WBGENE00002979
caenorhabditis_elegans	F30A10.3	WBGENE00009262

Paralogs (6): IP6K2 (ENSG00000068745), ITPKC (ENSG00000086544), ITPKA (ENSG00000137825), ITPKB (ENSG00000143772), IPMK (ENSG00000151151), IP6K3 (ENSG00000161896)

Protein

Protein identifiers

Inositol hexakisphosphate kinase 1 — Q92551 (reviewed: Q92551)

Alternative names: Inositol hexaphosphate kinase 1

All UniProt accessions (2): C9JNA8, Q92551

UniProt curated annotations — full annotation on UniProt →

Function. Converts inositol hexakisphosphate (InsP6) to diphosphoinositol pentakisphosphate (InsP7/PP-InsP5). Converts 1,3,4,5,6-pentakisphosphate (InsP5) to PP-InsP4.

Subcellular location. Cytoplasm. Nucleus.

Similarity. Belongs to the inositol phosphokinase (IPK) family.

Isoforms (2)

UniProt ID	Names	Canonical?
Q92551-1	1	yes
Q92551-2	2

RefSeq proteins (3): NP_001006115, NP_001229758, NP_695005* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR005522	IPK	Family
IPR038286	IPK_sf	Homologous_superfamily

Pfam: PF03770

Enzyme classification (BRENDA):

• EC 2.7.4.21 — inositol-hexakisphosphate 5-kinase (BRENDA: 10 organisms, 35 substrates, 31 inhibitors, 11 Km, 1 kcat entries)

Substrate kinetics (BRENDA)

6 substrates with measured Km, best-characterized 6. Km ranges are aggregated across organisms/conditions.

Substrate	Km (mM)	Measurements
ATP	0.037–1.4	4
INOSITOL HEXAKISPHOSPHATE	0.0007–0.0061	3
1D-MYO-INOSITOL HEXAKISPHOSPHATE	0.0004	1
5-DIPHOSPHO-1D-MYO-INOSITOL (1,2,3,4,6)PENTAKISP	0.002	1
ADP	1.57	1
D-MYO-INOSITOL-1,3,4,5,6-PENTAKISPHOSPHATE	0.0055	1

Catalyzed reactions (Rhea), 2 shown:

• 1D-myo-inositol hexakisphosphate + ATP = 5-diphospho-1D-myo-inositol 1,2,3,4,6-pentakisphosphate + ADP (RHEA:12793)
• 1-diphospho-1D-myo-inositol 2,3,4,5,6-pentakisphosphate + ATP + H(+) = 1,5-bis(diphospho)-1D-myo-inositol 2,3,4,6-tetrakisphosphate + ADP (RHEA:37467)

UniProt features (10 total): compositionally biased region 4, region of interest 2, chain 1, binding site 1, modified residue 1, splice variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q92551-F1	75.39	0.50

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (1): 220–228

Post-translational modifications (1): 151

Function

Pathways and Gene Ontology

Reactome pathways

4 pathways

ID	Pathway
R-HSA-1855167	Synthesis of pyrophosphates in the cytosol
R-HSA-1855191	Synthesis of IPs in the nucleus
R-HSA-1430728	Metabolism
R-HSA-1483249	Inositol phosphate metabolism

MSigDB gene sets: 203 (showing top): GGGACCA_MIR133A_MIR133B, MULLIGHAN_NPM1_SIGNATURE_3_UP, GOBP_PHOSPHOLIPID_METABOLIC_PROCESS, GOBP_PHOSPHATIDYLINOSITOL_METABOLIC_PROCESS, GOBP_INOSITOL_PHOSPHATE_METABOLIC_PROCESS, GOBP_POLYOL_METABOLIC_PROCESS, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_DN, GRAESSMANN_RESPONSE_TO_MC_AND_DOXORUBICIN_DN, GOBP_ORGANOPHOSPHATE_METABOLIC_PROCESS, GOBP_ORGANOPHOSPHATE_BIOSYNTHETIC_PROCESS, PATIL_LIVER_CANCER, GOBP_PHOSPHOLIPID_BIOSYNTHETIC_PROCESS, GOBP_GLYCEROLIPID_METABOLIC_PROCESS, GOBP_SMALL_MOLECULE_BIOSYNTHETIC_PROCESS, MARTINEZ_RB1_TARGETS_UP

GO Biological Process (6): inositol phosphate biosynthetic process (GO:0032958), inositol phosphate metabolic process (GO:0043647), phosphatidylinositol phosphate biosynthetic process (GO:0046854), negative regulation of cold-induced thermogenesis (GO:0120163), phosphatidylinositol metabolic process (GO:0046488), organophosphate biosynthetic process (GO:0090407)

GO Molecular Function (12): inositol-1,3,4,5,6-pentakisphosphate kinase activity (GO:0000827), inositol hexakisphosphate kinase activity (GO:0000828), diphosphoinositol pentakisphosphate kinase activity (GO:0000829), inositol hexakisphosphate 5-kinase activity (GO:0000832), ATP binding (GO:0005524), inositol 5-diphosphate pentakisphosphate 5-kinase activity (GO:0052836), diphosphoinositol tetrakisphosphate kinase activity (GO:0052839), nucleotide binding (GO:0000166), protein binding (GO:0005515), kinase activity (GO:0016301), transferase activity (GO:0016740), inositol phosphate kinase activity (GO:0180030)

GO Cellular Component (5): fibrillar center (GO:0001650), nucleus (GO:0005634), nucleoplasm (GO:0005654), cytoplasm (GO:0005737), cytosol (GO:0005829)

Reactome top-level categories

Rollup of top-2 pathways:

Category	Pathways
Inositol phosphate metabolism	2
Metabolism	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
inositol phosphate kinase activity	5
cellular anatomical structure	4
phosphotransferase activity, phosphate group as acceptor	3
organophosphate metabolic process	2
phosphotransferase activity, alcohol group as acceptor	2
inositol phosphate metabolic process	1
polyol biosynthetic process	1
organophosphate biosynthetic process	1
polyol metabolic process	1
glycerophospholipid biosynthetic process	1
negative regulation of multicellular organismal process	1
cold-induced thermogenesis	1
regulation of cold-induced thermogenesis	1
phosphorus metabolic process	1
biosynthetic process	1
inositol hexakisphosphate kinase activity	1
adenyl ribonucleotide binding	1
purine ribonucleoside triphosphate binding	1
nucleoside phosphate binding	1
heterocyclic compound binding	1
binding	1
transferase activity, transferring phosphorus-containing groups	1
catalytic activity	1
kinase activity	1
nucleolus	1
intracellular membrane-bounded organelle	1
nuclear lumen	1
intracellular anatomical structure	1
cytoplasm	1

Protein interactions and networks

STRING

1216 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
IP6K1	PPIP5K1	Q6PFW1	973
IP6K1	PPIP5K2	O43314	910
IP6K1	RAB3IL1	Q8TBN0	801
IP6K1	ITPKB	P27987	782
IP6K1	ITPKA	P23677	739
IP6K1	IPPK	Q9H8X2	625
IP6K1	ISYNA1	Q9NPH2	582
IP6K1	DDB1	Q16531	557
IP6K1	RNF123	Q5XPI4	542
IP6K1	INS	P01308	538
IP6K1	CDHR4	A6H8M9	528
IP6K1	ITPK1	Q13572	519
IP6K1	SYT1	P21579	507
IP6K1	PLIN1	O60240	495
IP6K1	CA4	P22748	494

IntAct

59 interactions, top by confidence:

A	B	Type	Score
CFTR	ESYT2	psi-mi:“MI:2364”(proximity)	0.710
VCP	UBXN8	psi-mi:“MI:0914”(association)	0.690
UBE4A	IP6K1	psi-mi:“MI:0915”(physical association)	0.680
EXOSC7	IP6K1	psi-mi:“MI:0915”(physical association)	0.670
IP6K1	EXOSC7	psi-mi:“MI:0915”(physical association)	0.670
VSIG1	TTI1	psi-mi:“MI:0914”(association)	0.640
UBXN4	UBE4A	psi-mi:“MI:0914”(association)	0.620
VIM	IP6K1	psi-mi:“MI:0915”(physical association)	0.560
ADAMTSL4	IP6K1	psi-mi:“MI:0915”(physical association)	0.560
IP6K1	PICK1	psi-mi:“MI:0915”(physical association)	0.560
RPL11	IP6K1	psi-mi:“MI:0915”(physical association)	0.560
GYPB	TCAF2	psi-mi:“MI:0914”(association)	0.530
DEFA5	NUDT19	psi-mi:“MI:0914”(association)	0.530
DEFA6	EXTL3	psi-mi:“MI:0914”(association)	0.530
CLMP	UTP20	psi-mi:“MI:0914”(association)	0.530
VSIG1	TNPO2	psi-mi:“MI:0914”(association)	0.530
IP6K2	IP6K1	psi-mi:“MI:0915”(physical association)	0.400
IP6K1	CACNA1A	psi-mi:“MI:0915”(physical association)	0.370
FGFR2	U2SURP	psi-mi:“MI:0914”(association)	0.350
UBXN4	UBE4A	psi-mi:“MI:0914”(association)	0.350
TFCP2	IP6K1	psi-mi:“MI:0914”(association)	0.350
M		psi-mi:“MI:0914”(association)	0.350
SEC61B	RPS3A	psi-mi:“MI:0914”(association)	0.350
VCL	UBXN8	psi-mi:“MI:0914”(association)	0.350
CD6	CIBAR1	psi-mi:“MI:0914”(association)	0.350

BioGRID (74): DDB1 (Affinity Capture-Western), IP6K1 (Reconstituted Complex), CUL4A (Affinity Capture-Western), RBX1 (Affinity Capture-Western), IP6K1 (Reconstituted Complex), IP6K1 (Reconstituted Complex), IP6K1 (Affinity Capture-MS), EXOSC7 (Two-hybrid), IP6K1 (Biochemical Activity), IP6K1 (Affinity Capture-MS), IP6K1 (Affinity Capture-MS), IP6K1 (Affinity Capture-MS), IP6K1 (Affinity Capture-MS), IP6K1 (Affinity Capture-MS), IP6K1 (Affinity Capture-MS)

ESM2 similar proteins: B0VX69, D3ZVU9, D4ABL6, E2RBS6, E9PTA2, E9PV86, G3V6U9, O15315, O54783, O54804, O55229, O94759, P35790, Q01134, Q04631, Q08DW9, Q13507, Q3UGX3, Q4R766, Q4R7M4, Q5R448, Q5TAQ9, Q5U2M6, Q5ZIA0, Q5ZIN0, Q61239, Q6AYT7, Q6DC64, Q6DN14, Q6PD10, Q7SXS7, Q7Z624, Q86W50, Q8CIW5, Q8N2K0, Q8NBA8, Q8NHH1, Q91WC0, Q91YD4, Q92551

Diamond homologs: O74561, Q12494, Q6PD10, Q80V72, Q8BWD2, Q92551, Q95221, Q96PC2, Q9ESM0, Q9R0U1, Q9UHH9, A2X5H5, Q6H545, Q7TT16, Q8NFU5, Q99NI4, Q9US14

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 54 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

GO biological processes:

GO term	Partners	Fold	FDR
ERAD pathway	6	23.1×	1e-04

Disease & clinical

Clinical variants and AI predictions

ClinVar

47 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	40
Likely benign	0
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

1719 predictions. Top by Δscore:

Variant	Effect	Δscore
3:49727653:CAC:C	acceptor_gain	1.0000
3:49728098:CTCA:C	donor_loss	1.0000
3:49728099:TCACC:T	donor_loss	1.0000
3:49728101:A:AC	donor_gain	1.0000
3:49728101:ACCT:A	donor_loss	1.0000
3:49728101:ACCTG:A	donor_gain	1.0000
3:49728102:C:A	donor_loss	1.0000
3:49728102:C:CT	donor_gain	1.0000
3:49728102:CCTG:C	donor_gain	1.0000
3:49728102:CCTGC:C	donor_gain	1.0000
3:49728277:CT:C	acceptor_gain	1.0000
3:49728285:C:CT	acceptor_gain	1.0000
3:49728288:G:T	acceptor_gain	1.0000
3:49728291:C:CT	acceptor_gain	1.0000
3:49728292:A:T	acceptor_gain	1.0000
3:49732765:T:A	donor_gain	1.0000
3:49732766:C:CA	donor_gain	1.0000
3:49732789:A:AC	donor_gain	1.0000
3:49732790:C:CC	donor_gain	1.0000
3:49732805:T:TA	donor_gain	1.0000
3:49732833:G:C	donor_gain	1.0000
3:49738207:CTTAC:C	donor_loss	1.0000
3:49738210:ACCTC:A	donor_loss	1.0000
3:49738211:CCT:C	donor_gain	1.0000
3:49738420:CGC:C	acceptor_gain	1.0000
3:49738423:C:CC	acceptor_gain	1.0000
3:49727656:CTGA:C	acceptor_loss	0.9900
3:49727657:T:G	acceptor_loss	0.9900
3:49727665:C:CT	acceptor_gain	0.9900
3:49727665:C:T	acceptor_gain	0.9900

AlphaMissense

2919 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
3:49727162:A:G	L429P	1.000
3:49727174:C:T	G425D	1.000
3:49727242:G:C	H402Q	1.000
3:49727242:G:T	H402Q	1.000
3:49727244:G:C	H402D	1.000
3:49727248:A:C	F400L	1.000
3:49727248:A:T	F400L	1.000
3:49727249:A:G	F400S	1.000
3:49727250:A:G	F400L	1.000
3:49727250:A:T	F400I	1.000
3:49727251:G:C	D399E	1.000
3:49727251:G:T	D399E	1.000
3:49727252:T:A	D399V	1.000
3:49727252:T:C	D399G	1.000
3:49727252:T:G	D399A	1.000
3:49727253:C:G	D399H	1.000
3:49727258:A:C	M397R	1.000
3:49727258:A:T	M397K	1.000
3:49727261:C:G	R396P	1.000
3:49727441:A:G	L336P	1.000
3:49727441:A:T	L336H	1.000
3:49727444:A:G	L335P	1.000
3:49727449:A:C	S333R	1.000
3:49727449:A:T	S333R	1.000
3:49727451:T:G	S333R	1.000
3:49727453:G:A	S332F	1.000
3:49727457:A:C	Y331D	1.000
3:49727459:A:G	F330S	1.000
3:49727462:C:G	R329P	1.000
3:49727463:G:T	R329S	1.000

dbSNP variants (sampled 300 via entrez): RS1000024504 (3:49726919 G>A), RS1000074637 (3:49754396 G>C), RS1000078248 (3:49774315 G>A), RS1000237234 (3:49754671 G>A), RS1000264222 (3:49748150 T>C), RS1000266204 (3:49777711 G>A,C), RS1000293739 (3:49754322 G>A), RS1000417584 (3:49747871 C>T), RS1000418006 (3:49785787 T>C), RS1000459649 (3:49726728 G>A), RS1000496636 (3:49733414 T>G), RS1000512803 (3:49745549 G>A), RS1000580828 (3:49753042 T>C), RS1000642204 (3:49782372 T>A,C), RS1000658357 (3:49779339 T>C)

Disease associations

OMIM: gene MIM:606991 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

27 associations (top):

Study	Trait	p-value
GCST001725_77	Inflammatory bowel disease	1.000000e-47
GCST002548_9	Ulcerative colitis	8.000000e-07
GCST003818_48	Resting heart rate	3.000000e-13
GCST005316_127	Intelligence (MTAG)	1.000000e-31
GCST005789_8	Resting heart rate	4.000000e-07
GCST005830_35	Hand grip strength	3.000000e-08
GCST005951_49	Body mass index	1.000000e-08
GCST006269_671	General cognitive ability	9.000000e-22
GCST006920_7	Regular attendance at a gym or sports club	6.000000e-10
GCST006922_9	Regular attendance at a religious group	3.000000e-08
GCST007044_11	Extremely high intelligence	4.000000e-08
GCST007094_14	Diastolic blood pressure	4.000000e-11
GCST007099_96	Systolic blood pressure	4.000000e-07
GCST007559_24	Sleep duration (short sleep)	3.000000e-08
GCST009449_22	Parental longevity (mother’s age at death or mother’s attained age)	7.000000e-10
GCST009524_143	Household income (MTAG)	5.000000e-26
GCST009524_71	Household income (MTAG)	2.000000e-08
GCST010002_422	Refractive error	4.000000e-14
GCST010698_80	Subcortical volume (min-P)	3.000000e-24
GCST010699_110	Brain morphology (min-P)	4.000000e-08
GCST010701_52	Cortical surface area (MOSTest)	1.000000e-16
GCST010702_36	Subcortical volume (MOSTest)	1.000000e-10
GCST010703_262	Brain morphology (MOSTest)	2.000000e-13
GCST90002385_424	High light scatter reticulocyte count	5.000000e-10
GCST90002386_544	High light scatter reticulocyte percentage of red cells	3.000000e-14
GCST90016671_2	Visceral adipose tissue volume	2.000000e-08
GCST90020026_195	Hip index	2.000000e-08

EFO canonical traits (11, from GWAS)

EFO ID	Trait name
EFO:0004337	intelligence
EFO:0006941	grip strength measurement
EFO:0004340	body mass index
EFO:0009592	social interaction measurement
EFO:0006336	diastolic blood pressure
EFO:0006335	systolic blood pressure
EFO:0007796	parental longevity
EFO:0009695	household income
EFO:0004346	neuroimaging measurement
EFO:0007986	reticulocyte count
EFO:0008039	BMI-adjusted hip circumference

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL4523418 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

Binding affinities (BindingDB)

173 measured of 199 human assays (199 total across all organisms); most potent 50 below. Values come from heterogeneous assays and are not directly comparable.

Ligand	Measure	Value	Patent
4’-[(3,5-dichloro-2-pyridinyl)oxy]-2-oxospiro[1H-indole-3,1’-cyclohexane]-5-carboxamide	IC50	55 nM	US-20250346572: NON-ACID INHIBITORS OF INOSITOL HEXAKISPHOSPHATE KINASE (IP6K) AND METHODS OF USE THEREOF
4’-[(3,5-dichloro-2-pyridinyl)oxy]-N-methyl-2-oxospiro[1H-indole-3,1’-cyclohexane]-5-carboxamide	IC50	55 nM	US-20250346572: NON-ACID INHIBITORS OF INOSITOL HEXAKISPHOSPHATE KINASE (IP6K) AND METHODS OF USE THEREOF
4’-[(3,5-dichloro-2-pyridinyl)oxy]-N-ethyl-2-oxospiro[1H-indole-3,1’-cyclohexane]-5-carboxamide	IC50	55 nM	US-20250346572: NON-ACID INHIBITORS OF INOSITOL HEXAKISPHOSPHATE KINASE (IP6K) AND METHODS OF USE THEREOF
N-cyclopropyl-4’-[(3,5-dichloro-2-pyridinyl)oxy]-2-oxospiro[1H-indole-3,1’-cyclohexane]-5-carboxamide	IC50	55 nM	US-20250346572: NON-ACID INHIBITORS OF INOSITOL HEXAKISPHOSPHATE KINASE (IP6K) AND METHODS OF USE THEREOF
4’-[(3,5-dichloro-2-pyridinyl)oxy]-5-(2H-tetrazol-5-yl)spiro[1H-indole-3,1’-cyclohexane]-2-one	IC50	55 nM	US-20250346572: NON-ACID INHIBITORS OF INOSITOL HEXAKISPHOSPHATE KINASE (IP6K) AND METHODS OF USE THEREOF
3-[4’-[(3,5-dichloro-2-pyridinyl)oxy]-2-oxospiro[1H-indole-3,1’-cyclohexane]-5-yl]-4H-1,2,4-oxadiazol-5-one	IC50	55 nM	US-20250346572: NON-ACID INHIBITORS OF INOSITOL HEXAKISPHOSPHATE KINASE (IP6K) AND METHODS OF USE THEREOF
4’-[(3,5-dichloro-2-pyridinyl)oxy]-N-methoxy-2-oxospiro[1H-indole-3,1’-cyclohexane]-5-carboxamide	IC50	55 nM	US-20250346572: NON-ACID INHIBITORS OF INOSITOL HEXAKISPHOSPHATE KINASE (IP6K) AND METHODS OF USE THEREOF
N-cyano-4’-[(3,5-dichloro-2-pyridinyl)oxy]-2-oxospiro[1H-indole-3,1’-cyclohexane]-5-carboxamide	IC50	55 nM	US-20250346572: NON-ACID INHIBITORS OF INOSITOL HEXAKISPHOSPHATE KINASE (IP6K) AND METHODS OF USE THEREOF
4’-[(3,5-dichloro-2-pyridinyl)oxy]-N-methylsulfonyl-2-oxospiro[1H-indole-3,1’-cyclohexane]-5-carboxamide	IC50	55 nM	US-20250346572: NON-ACID INHIBITORS OF INOSITOL HEXAKISPHOSPHATE KINASE (IP6K) AND METHODS OF USE THEREOF
N-cyclopropylsulfonyl-4’-[(3,5-dichloro-2-pyridinyl)oxy]-2-oxospiro[1H-indole-3,1’-cyclohexane]-5-carboxamide	IC50	55 nM	US-20250346572: NON-ACID INHIBITORS OF INOSITOL HEXAKISPHOSPHATE KINASE (IP6K) AND METHODS OF USE THEREOF
N-tert-butylsulfonyl-4’-[(3,5-dichloro-2-pyridinyl)oxy]-2-oxospiro[1H-indole-3,1’-cyclohexane]-5-carboxamide	IC50	55 nM	US-20250346572: NON-ACID INHIBITORS OF INOSITOL HEXAKISPHOSPHATE KINASE (IP6K) AND METHODS OF USE THEREOF
4’-[(5-chloro-3-cyano-2-pyridinyl)oxy]-N-ethyl-2-oxospiro[1H-indole-3,1’-cyclohexane]-5-carboxamide	IC50	55 nM	US-20250346572: NON-ACID INHIBITORS OF INOSITOL HEXAKISPHOSPHATE KINASE (IP6K) AND METHODS OF USE THEREOF
4’-[(3-chloro-5-cyano-2-pyridinyl)oxy]-N-ethyl-2-oxospiro[1H-indole-3,1’-cyclohexane]-5-carboxamide	IC50	55 nM	US-20250346572: NON-ACID INHIBITORS OF INOSITOL HEXAKISPHOSPHATE KINASE (IP6K) AND METHODS OF USE THEREOF
4’-[(5-chloro-3-fluoro-2-pyridinyl)oxy]-N-ethyl-2-oxospiro[1H-indole-3,1’-cyclohexane]-5-carboxamide	IC50	55 nM	US-20250346572: NON-ACID INHIBITORS OF INOSITOL HEXAKISPHOSPHATE KINASE (IP6K) AND METHODS OF USE THEREOF
4’-[(3,5-dichloro-2-pyridinyl)oxy]-2-oxospiro[1H-pyrrolo[3,2-b]pyridine-3,1’-cyclohexane]-5-carboxylic acid	IC50	55 nM	US-20250346572: NON-ACID INHIBITORS OF INOSITOL HEXAKISPHOSPHATE KINASE (IP6K) AND METHODS OF USE THEREOF
4’-[(3,5-dichloro-2-pyridinyl)oxy]-N-methyl-2-oxospiro[1H-pyrrolo[3,2-b]pyridine-3,1’-cyclohexane]-5-carboxamide	IC50	55 nM	US-20250346572: NON-ACID INHIBITORS OF INOSITOL HEXAKISPHOSPHATE KINASE (IP6K) AND METHODS OF USE THEREOF
4’-[(3,5-dichloro-2-pyridinyl)oxy]-6-fluoro-2-oxospiro[1H-indole-3,1’-cyclohexane]-5-carboxylic acid	IC50	55 nM	US-20250346572: NON-ACID INHIBITORS OF INOSITOL HEXAKISPHOSPHATE KINASE (IP6K) AND METHODS OF USE THEREOF
4’-[(3,5-dichloro-2-pyridinyl)oxy]-4-fluoro-2-oxospiro[1H-indole-3,1’-cyclohexane]-5-carboxylic acid	IC50	55 nM	US-20250346572: NON-ACID INHIBITORS OF INOSITOL HEXAKISPHOSPHATE KINASE (IP6K) AND METHODS OF USE THEREOF
4’-[(3,5-dichloro-2-pyridinyl)oxy]-4-fluoro-2-oxospiro[1H-indole-3,1’-cyclohexane]-5-carboxamide	IC50	55 nM	US-20250346572: NON-ACID INHIBITORS OF INOSITOL HEXAKISPHOSPHATE KINASE (IP6K) AND METHODS OF USE THEREOF
trans-(1R,2R)-2-[3-(3,5-dimethylphenyl)-2,1-benzoxazol-5-yl]cyclopropane-1-carboxylic acid	IC50	55 nM	US-20250154115: ARYLBENZOISOXAZOLE COMPOUNDS AS IP6K AND IPMK INHIBITORS AND METHODS OF USE THEREOF
N-methyl-3-(4-phenylphenyl)-2,1-benzoxazole-5-carboxamide	IC50	55 nM	US-20250154115: ARYLBENZOISOXAZOLE COMPOUNDS AS IP6K AND IPMK INHIBITORS AND METHODS OF USE THEREOF
3-phenyl-5-(2H-tetrazol-5-yl)-2,1-benzoxazole	IC50	55 nM	US-20250154115: ARYLBENZOISOXAZOLE COMPOUNDS AS IP6K AND IPMK INHIBITORS AND METHODS OF USE THEREOF
3-[3-(1-cyclobutylpiperidin-4-yl)oxyphenyl]-5-(2H-tetrazol-5-yl)-2,1-benzoxazole	IC50	55 nM	US-20250154115: ARYLBENZOISOXAZOLE COMPOUNDS AS IP6K AND IPMK INHIBITORS AND METHODS OF USE THEREOF
3-(4-fluorophenyl)-5-(2H-tetrazol-5-yl)-2,1-benzoxazole	IC50	55 nM	US-20250154115: ARYLBENZOISOXAZOLE COMPOUNDS AS IP6K AND IPMK INHIBITORS AND METHODS OF USE THEREOF
5-(2H-tetrazol-5-yl)-3-[4-(trifluoromethyl)phenyl]-2,1-benzoxazole	IC50	55 nM	US-20250154115: ARYLBENZOISOXAZOLE COMPOUNDS AS IP6K AND IPMK INHIBITORS AND METHODS OF USE THEREOF
3-(3,5-dimethylphenyl)-5-(2H-tetrazol-5-yl)-2,1-benzoxazole	IC50	55 nM	US-20250154115: ARYLBENZOISOXAZOLE COMPOUNDS AS IP6K AND IPMK INHIBITORS AND METHODS OF USE THEREOF
5-(2H-tetrazol-5-yl)-3-[4-(trifluoromethoxy)phenyl]-2,1-benzoxazole	IC50	55 nM	US-20250154115: ARYLBENZOISOXAZOLE COMPOUNDS AS IP6K AND IPMK INHIBITORS AND METHODS OF USE THEREOF
3-(3,4-dichlorophenyl)-5-(2H-tetrazol-5-yl)-2,1-benzoxazole	IC50	55 nM	US-20250154115: ARYLBENZOISOXAZOLE COMPOUNDS AS IP6K AND IPMK INHIBITORS AND METHODS OF USE THEREOF
3-(4-phenylphenyl)-5-(2H-tetrazol-5-yl)-2,1-benzoxazole	IC50	55 nM	US-20250154115: ARYLBENZOISOXAZOLE COMPOUNDS AS IP6K AND IPMK INHIBITORS AND METHODS OF USE THEREOF
3-(4-pyridin-3-ylphenyl)-5-(2H-tetrazol-5-yl)-2,1-benzoxazole	IC50	55 nM	US-20250154115: ARYLBENZOISOXAZOLE COMPOUNDS AS IP6K AND IPMK INHIBITORS AND METHODS OF USE THEREOF
N-[4-[5-(2H-tetrazol-5-yl)-2,1-benzoxazol-3-yl]phenyl]cyclopropanecarboxamide	IC50	55 nM	US-20250154115: ARYLBENZOISOXAZOLE COMPOUNDS AS IP6K AND IPMK INHIBITORS AND METHODS OF USE THEREOF
N-[4-[5-(2H-tetrazol-5-yl)-2,1-benzoxazol-3-yl]phenyl]cyclopentanecarboxamide	IC50	55 nM	US-20250154115: ARYLBENZOISOXAZOLE COMPOUNDS AS IP6K AND IPMK INHIBITORS AND METHODS OF USE THEREOF
N-[3-[5-(2H-tetrazol-5-yl)-2,1-benzoxazol-3-yl]phenyl]cyclopentanecarboxamide	IC50	55 nM	US-20250154115: ARYLBENZOISOXAZOLE COMPOUNDS AS IP6K AND IPMK INHIBITORS AND METHODS OF USE THEREOF
N-[3-[5-(2H-tetrazol-5-yl)-2,1-benzoxazol-3-yl]phenyl]cyclopropanecarboxamide	IC50	55 nM	US-20250154115: ARYLBENZOISOXAZOLE COMPOUNDS AS IP6K AND IPMK INHIBITORS AND METHODS OF USE THEREOF
3-(2-chlorophenyl)-5-(2H-tetrazol-5-yl)-2,1-benzoxazole	IC50	55 nM	US-20250154115: ARYLBENZOISOXAZOLE COMPOUNDS AS IP6K AND IPMK INHIBITORS AND METHODS OF USE THEREOF
3-(2-methoxyphenyl)-5-(2H-tetrazol-5-yl)-2,1-benzoxazole	IC50	55 nM	US-20250154115: ARYLBENZOISOXAZOLE COMPOUNDS AS IP6K AND IPMK INHIBITORS AND METHODS OF USE THEREOF
3-[3-[(3,5-dichloro-2-pyridinyl)oxy]phenyl]-5-(2H-tetrazol-5-yl)-2,1-benzoxazole	IC50	55 nM	US-20250154115: ARYLBENZOISOXAZOLE COMPOUNDS AS IP6K AND IPMK INHIBITORS AND METHODS OF USE THEREOF
tert-butyl 4-[3-[5-(2H-tetrazol-5-yl)-2,1-benzoxazol-3-yl]phenoxy]piperidine-1-carboxylate	IC50	55 nM	US-20250154115: ARYLBENZOISOXAZOLE COMPOUNDS AS IP6K AND IPMK INHIBITORS AND METHODS OF USE THEREOF
3-(3-piperidin-4-yloxyphenyl)-5-(2H-tetrazol-5-yl)-2,1-benzoxazole	IC50	55 nM	US-20250154115: ARYLBENZOISOXAZOLE COMPOUNDS AS IP6K AND IPMK INHIBITORS AND METHODS OF USE THEREOF
3-[3-(2-morpholin-4-ylethoxy)phenyl]-5-(2H-tetrazol-5-yl)-2,1-benzoxazole	IC50	55 nM	US-20250154115: ARYLBENZOISOXAZOLE COMPOUNDS AS IP6K AND IPMK INHIBITORS AND METHODS OF USE THEREOF
3-[3-(2,4-dichlorophenyl)phenyl]-5-(2H-tetrazol-5-yl)-2,1-benzoxazole	IC50	55 nM	US-20250154115: ARYLBENZOISOXAZOLE COMPOUNDS AS IP6K AND IPMK INHIBITORS AND METHODS OF USE THEREOF
3-[3-(1-methylpiperidin-4-yl)oxyphenyl]-5-(2H-tetrazol-5-yl)-2,1-benzoxazole	IC50	55 nM	US-20250154115: ARYLBENZOISOXAZOLE COMPOUNDS AS IP6K AND IPMK INHIBITORS AND METHODS OF USE THEREOF
3-[3-(1-propan-2-ylpiperidin-4-yl)oxyphenyl]-5-(2H-tetrazol-5-yl)-2,1-benzoxazole	IC50	55 nM	US-20250154115: ARYLBENZOISOXAZOLE COMPOUNDS AS IP6K AND IPMK INHIBITORS AND METHODS OF USE THEREOF
3-[3-[1-(cyclopropylmethyl)piperidin-4-yl]oxyphenyl]-5-(2H-tetrazol-5-yl)-2,1-benzoxazole	IC50	55 nM	US-20250154115: ARYLBENZOISOXAZOLE COMPOUNDS AS IP6K AND IPMK INHIBITORS AND METHODS OF USE THEREOF
cyclopropyl-[4-[3-[5-(2H-tetrazol-5-yl)-2,1-benzoxazol-3-yl]phenoxy]piperidin-1-yl]methanone	IC50	55 nM	US-20250154115: ARYLBENZOISOXAZOLE COMPOUNDS AS IP6K AND IPMK INHIBITORS AND METHODS OF USE THEREOF
2-methyl-1-[4-[3-[5-(2H-tetrazol-5-yl)-2,1-benzoxazol-3-yl]phenoxy]piperidin-1-yl]propan-1-one	IC50	55 nM	US-20250154115: ARYLBENZOISOXAZOLE COMPOUNDS AS IP6K AND IPMK INHIBITORS AND METHODS OF USE THEREOF
3-[3-[(3-methyloxetan-3-yl)methoxy]phenyl]-5-(2H-tetrazol-5-yl)-2,1-benzoxazole	IC50	55 nM	US-20250154115: ARYLBENZOISOXAZOLE COMPOUNDS AS IP6K AND IPMK INHIBITORS AND METHODS OF USE THEREOF
3-[3-(azetidin-3-yloxy)phenyl]-5-(2H-tetrazol-5-yl)-2,1-benzoxazole	IC50	55 nM	US-20250154115: ARYLBENZOISOXAZOLE COMPOUNDS AS IP6K AND IPMK INHIBITORS AND METHODS OF USE THEREOF
cyclopentyl-[4-[3-[5-(2H-tetrazol-5-yl)-2,1-benzoxazol-3-yl]phenoxy]piperidin-1-yl]methanone	IC50	55 nM	US-20250154115: ARYLBENZOISOXAZOLE COMPOUNDS AS IP6K AND IPMK INHIBITORS AND METHODS OF USE THEREOF
3-[4-[5-(2H-tetrazol-5-yl)-2,1-benzoxazol-3-yl]phenyl]aniline	IC50	55 nM	US-20250154115: ARYLBENZOISOXAZOLE COMPOUNDS AS IP6K AND IPMK INHIBITORS AND METHODS OF USE THEREOF

ChEMBL bioactivities

128 potent at pChembl≥5 of 164 total, top 50 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
8.77	IC50	1.7	nM	CHEMBL5598155
8.60	IC50	2.5	nM	CHEMBL5598038
8.54	IC50	2.9	nM	CHEMBL5190343
8.49	IC50	3.2	nM	CHEMBL5596194
8.44	IC50	3.6	nM	CHEMBL5590726
8.19	IC50	6.5	nM	CHEMBL5598068
8.16	IC50	6.9	nM	CHEMBL5598514
8.10	IC50	7.9	nM	CHEMBL5597913
8.10	IC50	8	nM	CHEMBL5596094
8.05	IC50	8.9	nM	CHEMBL5190343
8.03	IC50	9.3	nM	CHEMBL5598435
7.80	IC50	16	nM	CHEMBL5597090
7.80	IC50	16	nM	CHEMBL5590042
7.58	IC50	26	nM	CHEMBL5169462
7.57	IC50	27	nM	CHEMBL5181623
7.57	IC50	27	nM	CHEMBL5203174
7.57	IC50	27	nM	CHEMBL5598271
7.55	IC50	28	nM	CHEMBL5596469
7.55	IC50	28	nM	CHEMBL5597088
7.52	IC50	30	nM	CHEMBL5596929
7.51	IC50	31	nM	CHEMBL5597637
7.46	IC50	35	nM	CHEMBL5596184
7.44	IC50	36	nM	CHEMBL5596237
7.41	IC50	39	nM	CHEMBL5596303
7.37	IC50	43	nM	CHEMBL5597391
7.24	IC50	57	nM	CHEMBL5190343
7.18	IC50	66	nM	CHEMBL5598451
7.17	IC50	68	nM	CHEMBL5596764
7.11	IC50	78	nM	CHEMBL5200214
7.11	IC50	78	nM	CHEMBL5596496
7.11	IC50	77	nM	CHEMBL5596099
7.09	IC50	81	nM	CHEMBL5184940
7.08	IC50	84	nM	CHEMBL5204881
7.08	IC50	83	nM	CHEMBL5596638
7.05	IC50	90	nM	CHEMBL5598241
6.96	IC50	110	nM	CHEMBL5186210
6.96	IC50	110	nM	CHEMBL5597127
6.89	IC50	130	nM	CHEMBL5201056
6.89	IC50	130	nM	CHEMBL5184960
6.89	IC50	130	nM	CHEMBL5597596
6.85	IC50	140	nM	CHEMBL5596437
6.85	IC50	140	nM	CHEMBL5596161
6.82	IC50	150	nM	CHEMBL5597163
6.80	IC50	160	nM	CHEMBL5190846
6.80	IC50	160	nM	CHEMBL5596215
6.80	IC50	160	nM	CHEMBL5597747
6.80	IC50	160	nM	CHEMBL5596409
6.77	IC50	170	nM	CHEMBL5201078
6.77	IC50	170	nM	CHEMBL5196483
6.75	IC50	180	nM	CHEMBL5598518

PubChem BioAssay actives

128 with measured affinity, of 206 total; 50 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
4’-[(3,5-dichloro-2-pyridinyl)oxy]-N-methylsulfonyl-2-oxospiro[1H-indole-3,1’-cyclohexane]-5-carboxamide	2121103: Inhibition of IP6K1 (unknown origin) using IP6 as substrate incubated for 30 mins in presence of ATP by ADPGlo enzymatic assay	ic50	0.0017	uM
4’-[(3,5-dichloro-2-pyridinyl)oxy]-2-oxospiro[1H-indole-3,1’-cyclohexane]-5-carboxylic acid	2121103: Inhibition of IP6K1 (unknown origin) using IP6 as substrate incubated for 30 mins in presence of ATP by ADPGlo enzymatic assay	ic50	0.0025	uM
3-(4-phenylphenyl)-2,1-benzoxazole-5-carboxylic acid	2121103: Inhibition of IP6K1 (unknown origin) using IP6 as substrate incubated for 30 mins in presence of ATP by ADPGlo enzymatic assay	ic50	0.0029	uM
4’-[(5-chloro-3-cyano-2-pyridinyl)oxy]-N-ethyl-2-oxospiro[1H-indole-3,1’-cyclohexane]-5-carboxamide	2121103: Inhibition of IP6K1 (unknown origin) using IP6 as substrate incubated for 30 mins in presence of ATP by ADPGlo enzymatic assay	ic50	0.0032	uM
4’-[(3,5-dichloro-2-pyridinyl)oxy]-6-fluoro-2-oxospiro[1H-indole-3,1’-cyclohexane]-5-carboxylic acid	2121103: Inhibition of IP6K1 (unknown origin) using IP6 as substrate incubated for 30 mins in presence of ATP by ADPGlo enzymatic assay	ic50	0.0036	uM
4’-[(3,5-dichloro-2-pyridinyl)oxy]-2-oxospiro[1H-pyrrolo[3,2-b]pyridine-3,1’-cyclohexane]-5-carboxylic acid	2121103: Inhibition of IP6K1 (unknown origin) using IP6 as substrate incubated for 30 mins in presence of ATP by ADPGlo enzymatic assay	ic50	0.0065	uM
4’-[(3,5-dichloro-2-pyridinyl)oxy]-4-fluoro-2-oxospiro[1H-indole-3,1’-cyclohexane]-5-carboxylic acid	2121103: Inhibition of IP6K1 (unknown origin) using IP6 as substrate incubated for 30 mins in presence of ATP by ADPGlo enzymatic assay	ic50	0.0069	uM
4’-[(3,5-dichloro-2-pyridinyl)oxy]-5-(2H-tetrazol-5-yl)spiro[1H-indole-3,1’-cyclohexane]-2-one	2121103: Inhibition of IP6K1 (unknown origin) using IP6 as substrate incubated for 30 mins in presence of ATP by ADPGlo enzymatic assay	ic50	0.0079	uM
N-cyano-4’-[(3,5-dichloro-2-pyridinyl)oxy]-2-oxospiro[1H-indole-3,1’-cyclohexane]-5-carboxamide	2121103: Inhibition of IP6K1 (unknown origin) using IP6 as substrate incubated for 30 mins in presence of ATP by ADPGlo enzymatic assay	ic50	0.0080	uM
3-[4’-[(3,5-dichloro-2-pyridinyl)oxy]-2-oxospiro[1H-indole-3,1’-cyclohexane]-5-yl]-4H-1,2,4-oxadiazol-5-one	2121103: Inhibition of IP6K1 (unknown origin) using IP6 as substrate incubated for 30 mins in presence of ATP by ADPGlo enzymatic assay	ic50	0.0093	uM
4’-[(3,5-dicyano-2-pyridinyl)oxy]-N-ethyl-2-oxospiro[1H-indole-3,1’-cyclohexane]-5-carboxamide	2121103: Inhibition of IP6K1 (unknown origin) using IP6 as substrate incubated for 30 mins in presence of ATP by ADPGlo enzymatic assay	ic50	0.0160	uM
4’-[(3,5-dichloro-2-pyridinyl)oxy]-4-fluoro-2-oxospiro[1H-indole-3,1’-cyclohexane]-5-carboxamide	2121103: Inhibition of IP6K1 (unknown origin) using IP6 as substrate incubated for 30 mins in presence of ATP by ADPGlo enzymatic assay	ic50	0.0160	uM
3-(4-pyridin-3-ylphenyl)-2,1-benzoxazole-5-carboxylic acid	1909468: Inhibition of N-terminal 6His-MBP-tagged recombinant human IP6K1 expressed in Escherichia coli assessed as inorganic phosphate release using InsP6 as substrate in presence of ATP measured after 60 to 120 mins by malachite green based colorimetric - DIPP1 coupled enzyme assay	ic50	0.0260	uM
1’-(4-chlorobenzoyl)-2-oxospiro[1H-indole-3,4’-piperidine]-5-carboxylic acid	1909473: Inhibition of recombinant full length human IP6K1 assessed as inorganic phosphate release measured after 30 mins by ADP-Glo Max assay	ic50	0.0270	uM
(E)-3-[3-(4-phenylphenyl)-2,1-benzoxazol-5-yl]prop-2-enoic acid	1909468: Inhibition of N-terminal 6His-MBP-tagged recombinant human IP6K1 expressed in Escherichia coli assessed as inorganic phosphate release using InsP6 as substrate in presence of ATP measured after 60 to 120 mins by malachite green based colorimetric - DIPP1 coupled enzyme assay	ic50	0.0270	uM
4’-[(3,5-dichloro-2-pyridinyl)oxy]-N-methoxy-2-oxospiro[1H-indole-3,1’-cyclohexane]-5-carboxamide	2121103: Inhibition of IP6K1 (unknown origin) using IP6 as substrate incubated for 30 mins in presence of ATP by ADPGlo enzymatic assay	ic50	0.0270	uM
4’-[(3,5-dichloro-2-pyridinyl)oxy]-2-oxospiro[1H-indole-3,1’-cyclohexane]-5-carboxamide	2121103: Inhibition of IP6K1 (unknown origin) using IP6 as substrate incubated for 30 mins in presence of ATP by ADPGlo enzymatic assay	ic50	0.0280	uM
3-(4-phenylphenyl)-2,1-benzoxazole-5-carboxamide	2121103: Inhibition of IP6K1 (unknown origin) using IP6 as substrate incubated for 30 mins in presence of ATP by ADPGlo enzymatic assay	ic50	0.0280	uM
4’-[(3-chloro-5-cyano-2-pyridinyl)oxy]-N-ethyl-2-oxospiro[1H-indole-3,1’-cyclohexane]-5-carboxamide	2121103: Inhibition of IP6K1 (unknown origin) using IP6 as substrate incubated for 30 mins in presence of ATP by ADPGlo enzymatic assay	ic50	0.0300	uM
1’-[(2,4-dichlorophenyl)methyl]-2-oxospiro[1H-indole-3,4’-piperidine]-5-carboxylic acid	2121103: Inhibition of IP6K1 (unknown origin) using IP6 as substrate incubated for 30 mins in presence of ATP by ADPGlo enzymatic assay	ic50	0.0310	uM
N-tert-butylsulfonyl-4’-[(3,5-dichloro-2-pyridinyl)oxy]-2-oxospiro[1H-indole-3,1’-cyclohexane]-5-carboxamide	2121103: Inhibition of IP6K1 (unknown origin) using IP6 as substrate incubated for 30 mins in presence of ATP by ADPGlo enzymatic assay	ic50	0.0350	uM
4’-[(3,5-dichloro-2-pyridinyl)oxy]-N-ethyl-2-oxospiro[1H-indole-3,1’-cyclohexane]-5-carboxamide	2121103: Inhibition of IP6K1 (unknown origin) using IP6 as substrate incubated for 30 mins in presence of ATP by ADPGlo enzymatic assay	ic50	0.0360	uM
4’-[(3,5-dichloro-2-pyridinyl)oxy]-5-(2-oxo-5H-1,2,3,5-oxathiadiazol-4-yl)spiro[1H-indole-3,1’-cyclohexane]-2-one	2121103: Inhibition of IP6K1 (unknown origin) using IP6 as substrate incubated for 30 mins in presence of ATP by ADPGlo enzymatic assay	ic50	0.0390	uM
N-(benzenesulfonyl)-4’-[(3,5-dichloro-2-pyridinyl)oxy]-2-oxospiro[1H-indole-3,1’-cyclohexane]-5-carboxamide	2121103: Inhibition of IP6K1 (unknown origin) using IP6 as substrate incubated for 30 mins in presence of ATP by ADPGlo enzymatic assay	ic50	0.0430	uM
N-cyclopropylsulfonyl-4’-[(3,5-dichloro-2-pyridinyl)oxy]-2-oxospiro[1H-indole-3,1’-cyclohexane]-5-carboxamide	2121103: Inhibition of IP6K1 (unknown origin) using IP6 as substrate incubated for 30 mins in presence of ATP by ADPGlo enzymatic assay	ic50	0.0660	uM
N-cyclopropyl-4’-[(3,5-dichloro-2-pyridinyl)oxy]-2-oxospiro[1H-indole-3,1’-cyclohexane]-5-carboxamide	2121103: Inhibition of IP6K1 (unknown origin) using IP6 as substrate incubated for 30 mins in presence of ATP by ADPGlo enzymatic assay	ic50	0.0680	uM
4’-[(3,5-dichloro-2-pyridinyl)oxy]-N-methyl-2-oxospiro[1H-pyrrolo[3,2-b]pyridine-3,1’-cyclohexane]-5-carboxamide	2121103: Inhibition of IP6K1 (unknown origin) using IP6 as substrate incubated for 30 mins in presence of ATP by ADPGlo enzymatic assay	ic50	0.0770	uM
3-[3-[(3,5-dichloro-2-pyridinyl)oxy]phenyl]-2,1-benzoxazole-5-carboxylic acid	1909468: Inhibition of N-terminal 6His-MBP-tagged recombinant human IP6K1 expressed in Escherichia coli assessed as inorganic phosphate release using InsP6 as substrate in presence of ATP measured after 60 to 120 mins by malachite green based colorimetric - DIPP1 coupled enzyme assay	ic50	0.0780	uM
4’-[(3,5-dichloro-2-pyridinyl)oxy]-N-methyl-2-oxospiro[1H-indole-3,1’-cyclohexane]-5-carboxamide	2121103: Inhibition of IP6K1 (unknown origin) using IP6 as substrate incubated for 30 mins in presence of ATP by ADPGlo enzymatic assay	ic50	0.0780	uM
3-(3-phenylphenyl)-2,1-benzoxazole-5-carboxylic acid	1909468: Inhibition of N-terminal 6His-MBP-tagged recombinant human IP6K1 expressed in Escherichia coli assessed as inorganic phosphate release using InsP6 as substrate in presence of ATP measured after 60 to 120 mins by malachite green based colorimetric - DIPP1 coupled enzyme assay	ic50	0.0810	uM
4’-[(5-chloro-3-fluoro-2-pyridinyl)oxy]-N-ethyl-2-oxospiro[1H-indole-3,1’-cyclohexane]-5-carboxamide	2121103: Inhibition of IP6K1 (unknown origin) using IP6 as substrate incubated for 30 mins in presence of ATP by ADPGlo enzymatic assay	ic50	0.0830	uM
3-(3,5-dimethylphenyl)-2,1-benzoxazole-5-carboxylic acid	1909468: Inhibition of N-terminal 6His-MBP-tagged recombinant human IP6K1 expressed in Escherichia coli assessed as inorganic phosphate release using InsP6 as substrate in presence of ATP measured after 60 to 120 mins by malachite green based colorimetric - DIPP1 coupled enzyme assay	ic50	0.0840	uM
4’-[(3,5-dichloro-2-pyridinyl)oxy]-N-(2-methoxyethyl)-2-oxospiro[1H-indole-3,1’-cyclohexane]-5-carboxamide	2121103: Inhibition of IP6K1 (unknown origin) using IP6 as substrate incubated for 30 mins in presence of ATP by ADPGlo enzymatic assay	ic50	0.0900	uM
3-(4-benzylphenyl)-2,1-benzoxazole-5-carboxylic acid	1909468: Inhibition of N-terminal 6His-MBP-tagged recombinant human IP6K1 expressed in Escherichia coli assessed as inorganic phosphate release using InsP6 as substrate in presence of ATP measured after 60 to 120 mins by malachite green based colorimetric - DIPP1 coupled enzyme assay	ic50	0.1100	uM
4’-[(3,5-dichloro-2-pyridinyl)oxy]-2-oxospiro[1H-pyrrolo[3,2-b]pyridine-3,1’-cyclohexane]-5-carboxamide	2121103: Inhibition of IP6K1 (unknown origin) using IP6 as substrate incubated for 30 mins in presence of ATP by ADPGlo enzymatic assay	ic50	0.1100	uM
(E)-3-[3-(4-phenoxyphenyl)-2,1-benzoxazol-5-yl]prop-2-enoic acid	1909468: Inhibition of N-terminal 6His-MBP-tagged recombinant human IP6K1 expressed in Escherichia coli assessed as inorganic phosphate release using InsP6 as substrate in presence of ATP measured after 60 to 120 mins by malachite green based colorimetric - DIPP1 coupled enzyme assay	ic50	0.1300	uM
(E)-3-[3-[4-(trifluoromethoxy)phenyl]-2,1-benzoxazol-5-yl]prop-2-enoic acid	1909468: Inhibition of N-terminal 6His-MBP-tagged recombinant human IP6K1 expressed in Escherichia coli assessed as inorganic phosphate release using InsP6 as substrate in presence of ATP measured after 60 to 120 mins by malachite green based colorimetric - DIPP1 coupled enzyme assay	ic50	0.1300	uM
N-cyclobutyl-4’-[(3,5-dichloro-2-pyridinyl)oxy]-2-oxospiro[1H-indole-3,1’-cyclohexane]-5-carboxamide	2121103: Inhibition of IP6K1 (unknown origin) using IP6 as substrate incubated for 30 mins in presence of ATP by ADPGlo enzymatic assay	ic50	0.1300	uM
4’-[(3,5-dichloro-2-pyridinyl)oxy]-2-oxo-N-propylspiro[1H-indole-3,1’-cyclohexane]-5-carboxamide	2121103: Inhibition of IP6K1 (unknown origin) using IP6 as substrate incubated for 30 mins in presence of ATP by ADPGlo enzymatic assay	ic50	0.1400	uM
4’-[(5-cyano-2-pyridinyl)oxy]-N-ethyl-2-oxospiro[1H-indole-3,1’-cyclohexane]-5-carboxamide	2121103: Inhibition of IP6K1 (unknown origin) using IP6 as substrate incubated for 30 mins in presence of ATP by ADPGlo enzymatic assay	ic50	0.1400	uM
1’-[(2,4-dichlorophenyl)methyl]-2-oxospiro[1H-indole-3,4’-piperidine]-5-carboxamide	2121103: Inhibition of IP6K1 (unknown origin) using IP6 as substrate incubated for 30 mins in presence of ATP by ADPGlo enzymatic assay	ic50	0.1500	uM
(E)-3-[3-(3-methylphenyl)-2,1-benzoxazol-5-yl]prop-2-enoic acid	1909468: Inhibition of N-terminal 6His-MBP-tagged recombinant human IP6K1 expressed in Escherichia coli assessed as inorganic phosphate release using InsP6 as substrate in presence of ATP measured after 60 to 120 mins by malachite green based colorimetric - DIPP1 coupled enzyme assay	ic50	0.1600	uM
4’-[(5-chloro-2-pyridinyl)oxy]-N-ethyl-2-oxospiro[1H-indole-3,1’-cyclohexane]-5-carboxamide	2121103: Inhibition of IP6K1 (unknown origin) using IP6 as substrate incubated for 30 mins in presence of ATP by ADPGlo enzymatic assay	ic50	0.1600	uM
4’-[(3-cyano-2-pyridinyl)oxy]-N-ethyl-2-oxospiro[1H-indole-3,1’-cyclohexane]-5-carboxamide	2121103: Inhibition of IP6K1 (unknown origin) using IP6 as substrate incubated for 30 mins in presence of ATP by ADPGlo enzymatic assay	ic50	0.1600	uM
4’-[(3-chloro-2-pyridinyl)oxy]-N-ethyl-2-oxospiro[1H-indole-3,1’-cyclohexane]-5-carboxamide	2121103: Inhibition of IP6K1 (unknown origin) using IP6 as substrate incubated for 30 mins in presence of ATP by ADPGlo enzymatic assay	ic50	0.1600	uM
3-(3-phenoxyphenyl)-2,1-benzoxazole-5-carboxylic acid	1909468: Inhibition of N-terminal 6His-MBP-tagged recombinant human IP6K1 expressed in Escherichia coli assessed as inorganic phosphate release using InsP6 as substrate in presence of ATP measured after 60 to 120 mins by malachite green based colorimetric - DIPP1 coupled enzyme assay	ic50	0.1700	uM
3-(4-pyridin-4-ylphenyl)-2,1-benzoxazole-5-carboxylic acid	1909468: Inhibition of N-terminal 6His-MBP-tagged recombinant human IP6K1 expressed in Escherichia coli assessed as inorganic phosphate release using InsP6 as substrate in presence of ATP measured after 60 to 120 mins by malachite green based colorimetric - DIPP1 coupled enzyme assay	ic50	0.1700	uM
4’-[(3,5-dichloro-2-pyridinyl)oxy]-N-ethyl-2-oxospiro[1H-pyrrolo[3,2-b]pyridine-3,1’-cyclohexane]-5-carboxamide	2121103: Inhibition of IP6K1 (unknown origin) using IP6 as substrate incubated for 30 mins in presence of ATP by ADPGlo enzymatic assay	ic50	0.1800	uM
3-[4-(cyclopentanecarbonylamino)phenyl]-2,1-benzoxazole-5-carboxylic acid	1909468: Inhibition of N-terminal 6His-MBP-tagged recombinant human IP6K1 expressed in Escherichia coli assessed as inorganic phosphate release using InsP6 as substrate in presence of ATP measured after 60 to 120 mins by malachite green based colorimetric - DIPP1 coupled enzyme assay	ic50	0.1900	uM
4’-[(3-chloro-5-fluoro-2-pyridinyl)oxy]-N-ethyl-2-oxospiro[1H-indole-3,1’-cyclohexane]-5-carboxamide	2121103: Inhibition of IP6K1 (unknown origin) using IP6 as substrate incubated for 30 mins in presence of ATP by ADPGlo enzymatic assay	ic50	0.1900	uM

CTD chemical–gene interactions

22 total (human), top 22 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
triphenyl phosphate	affects expression	1
alpha-pinene	increases abundance, affects cotreatment, increases expression	1
sodium arsenite	increases abundance, affects cotreatment, decreases expression	1
manganese chloride	increases abundance, affects cotreatment, decreases expression	1
oxophenylarsine	decreases activity	1
methacrylaldehyde	affects cotreatment, increases expression, increases abundance	1
beta-methylcholine	affects expression	1
1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione	decreases activity	1
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	decreases activity	1
abrine	increases expression	1
mono(carboxy-isooctyl)phthalate	affects expression	1
Acrolein	increases abundance, affects cotreatment, increases expression	1
Air Pollutants	affects cotreatment, increases abundance, increases expression	1
Arsenic	affects cotreatment, decreases expression, increases abundance	1
Atrazine	decreases expression	1
Hydrogen Peroxide	affects expression	1
Manganese	decreases expression, increases abundance, affects cotreatment	1
Ozone	affects cotreatment, increases expression, increases abundance	1
Urethane	increases expression	1
Copper Sulfate	decreases expression	1
Acrylamide	increases expression	1
Volatile Organic Compounds	affects cotreatment, increases expression	1

ChEMBL screening assays

11 unique, capped per target: 11 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL4400032	Binding	Inhibition of IP6K1 (unknown origin) in presence of ATP at Km concentration by Cheng-Prusoff equation analysis	Synthesis and characterization of novel isoform-selective IP6K1 inhibitors. — Bioorg Med Chem Lett

Cellosaurus cell lines

2 cell lines: 1 cancer cell line, 1 transformed cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_D7SD	Ubigene A-549 IP6K1 KO	Cancer cell line	Male
CVCL_D9HB	Ubigene HEK293 IP6K1 KO	Transformed cell line	Female

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.